Content area
Full Text
Alessandro Riva is set to leave Gilead to take up the CEO role at Glenmark Pharmaceuticals’ new spinoff. The Indian drugmaker’s hiring coup leaves Gilead without the oncology leader that oversaw its takeover of Kite Pharma and push into CAR-T.
Riva arrived at Gilead at the start of 2017 with a brief to energize its floundering oncology unit by swiftly identifying and landing takeover targets. Within eight months of Riva’s arrival, Gilead unveiled its $11.9 billion takeover of Kite Pharma. The deal established Gilead as the chief rival to Novartis, the former employer of Riva, in the emerging CAR-T sector.
Now, Riva is moving on again. The...